Sessions are scheduled in local time (CEST)

Browsing Over 485 Presentations

Sort By
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?

Questions and take-home messages (ID 503)

Lecture Time
12:30 - 12:30
Session Name
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • All Speakers (na, Switzerland)
Authors
  • All Speakers (na, Switzerland)
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease?

Introduction (ID 66)

Lecture Time
11:30 - 11:35
Session Name
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease?
Room
Munich Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Javier Cortes (Madrid and Barcelona, Spain)
Authors
  • Javier Cortes (Madrid and Barcelona, Spain)
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?

Welcome and introductions (ID 498)

Lecture Time
11:30 - 12:30
Session Name
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • All Speakers (na, Switzerland)
Authors
  • All Speakers (na, Switzerland)
Novartis - Decision-making in a dynamic treatment landscape: Discussions on challenging patient cases in HR+/HER2- advanced breast cancer

Welcome and introductions (ID 12)

Lecture Time
11:30 - 11:35
Session Name
Novartis - Decision-making in a dynamic treatment landscape: Discussions on challenging patient cases in HR+/HER2- advanced breast cancer
Room
Frankfurt Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Sherko Kuemmel (Essen, Germany)
Authors
  • Sherko Kuemmel (Essen, Germany)
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease?

Reacting to a dynamic disease (ID 67)

Lecture Time
11:35 - 11:45
Session Name
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease?
Room
Munich Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Komal Jhaveri (New York, NY, United States of America)
Authors
  • Komal Jhaveri (New York, NY, United States of America)
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?

Assessing risk of recurrence in HR-positive, HER2-negative early breast cancer (ID 499)

Lecture Time
12:30 - 12:30
Session Name
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • All Speakers (na, Switzerland)
Authors
  • All Speakers (na, Switzerland)
Novartis - Decision-making in a dynamic treatment landscape: Discussions on challenging patient cases in HR+/HER2- advanced breast cancer

First-line treatment in HR+/HER2- ABC: Patient cases (ID 13)

Lecture Time
11:35 - 12:00
Session Name
Novartis - Decision-making in a dynamic treatment landscape: Discussions on challenging patient cases in HR+/HER2- advanced breast cancer
Room
Frankfurt Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Sherko Kuemmel (Essen, Germany)
Authors
  • Sherko Kuemmel (Essen, Germany)
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease?

Moving ahead of a dynamic disease (ID 68)

Lecture Time
11:45 - 11:55
Session Name
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease?
Room
Munich Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • François Clément Bidard (Paris, CE, France)
Authors
  • François Clément Bidard (Paris, CE, France)
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?

Impact of oral targeted adjuvant therapies in patients with HR-positive, HER2-negative early breast cancer (ID 500)

Lecture Time
12:30 - 12:30
Session Name
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • All Speakers (na, Switzerland)
Authors
  • All Speakers (na, Switzerland)
Novartis - Decision-making in a dynamic treatment landscape: Discussions on challenging patient cases in HR+/HER2- advanced breast cancer

Sequencing following progression after first-line CDK4/6i: Patient cases (ID 14)

Lecture Time
12:00 - 12:20
Session Name
Novartis - Decision-making in a dynamic treatment landscape: Discussions on challenging patient cases in HR+/HER2- advanced breast cancer
Room
Frankfurt Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Michelino De Laurentiis (Napoli, Italy)
Authors
  • Michelino De Laurentiis (Napoli, Italy)
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease?

Gaining momentum with new modalities (ID 69)

Lecture Time
11:55 - 12:05
Session Name
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease?
Room
Munich Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Javier Cortes (Madrid and Barcelona, Spain)
Authors
  • Javier Cortes (Madrid and Barcelona, Spain)
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?

Optimizing adherence and persistence with oral targeted adjuvant therapies in HR-positive, HER2-negative early breast cancer (ID 501)

Lecture Time
12:30 - 12:30
Session Name
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • All Speakers (na, Switzerland)
Authors
  • All Speakers (na, Switzerland)